|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Shionogi: PharmaVitae Profile |
|
|
|
|
€ 4 560,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Décembre 2006 |
Taille du document : |
125 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (1) |
|
|
|
| 51 pages | Septembre 2008 | Anglais
|
|
|
| Main
focus: |
infectious diseases,infectious disease,vaccine,...,...
|
| Research
focus: |
industry structure,market segmentation, |
| Geographic
focus: |
usa,india,united kingdom,kenya,indonesia,... |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Maximising the Drug Lifecycle
102 pages | Août 2001 |
Up to $100bn of the 2000 pharmaceutical market, including blockbuster drugs with combined sales of $34bn will be exposed to generic competition by 2005.Maximising The Drug Lifecycle provides a detaile |
955,00 €
|
| |
| |
Healthcare In Wales
50 pages | Mai 2000 |
The Welsh Presentation Includes:- The Structure Of The NHS In Wales- Revenue Expenditure On Health Services In Wales- Number Of Hospital Units - Number Of Available Inpatient Beds- Number Of Occupied |
327,00 €
|
| |
| |
Pharmaceutical Pricing Strategies 2000: Entering the new millennium
240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once a company's freedom over pricing decisions was almost limitless, external pressure |
955,00 €
|
| |
| |
Generic Pharmaceutical Outlook 1998-2008
190 pages | Octobre 1998 |
Currently estimated to account for approximately 11% of Global pharmaceutical sales, this figure looks set to rise dramatically as branded drugs come off-patent within the next decade.
Imminent |
795,00 €
|
| |
| |
Pharmaceutical Packaging Market
80 pages | Avril 2002 |
This report will enable you to:Analyse the size of the UK market for pharmaceutical packaging between 1997 and 2006, by type: - cartons - containers - labels and leaflets - blister & strip p |
1 479,00 €
|
| |
| |
The Pharmaceutical Mergers and Acquisitions Outlook 2001
128 pages | Octobre 2001 |
Pharmaceutical companies have recently undertaken extensive M&A activity to either build critical mass, create organic growth or through strategic alliances to build virtual mass.
The Pharmaceu |
1 200,00 €
|
| |
| |
Bridging the Pharmaceutical Earnings gap: Key Strategies in the race for growth
173 pages | Mars 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once near unrestricted revenue expansion existed, external pressures now act in unison |
955,00 €
|
| |
| |
The Evolution of DTC marketing across key pharmaceutical markets
152 pages | Mars 2000 |
Pharmaceutical companies mainly market their products through contact between their sales force and heathcare providers.
However, due to the nature of its products, the pharmaceutical industry |
955,00 €
|
| |
| |
Chinese Markets for Pharmaceuticals
225 pages | Janvier 2002 |
China's demand for pharmaceuticals has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic |
2 835,00 €
|
| |
| |
Strategic Intelligence: The Top 12 Pharmaceutical Companies
158 pages | Novembre 2001 |
The pressure on the pharmaceutical company R&D has never been greater.
It is estimated that $100 billion worth of products will face patent expiry by 2005.
Of this, $37 billion represe |
1 021,89 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Shionogi: PharmaVitae Profile |
|
|
Introduction
This analysis examines the historical and forecast performance for Shionogi in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Shionogi's performance against key rivals in the ethical pharmaceutical sector
*See how the company will benefit from the influx of Crestor royalties from AstraZeneca's international sales
*Assess the impact of the expiry of key infectious disease products Flomox and Flumarin on Shionogi's sales growth
|
|
Shionogi: PharmaVitae Profile
|
|
|
PPLSEN
|
|
|
|
|
